SEBI warns Aurobindo Pharma over U.S. FDA audit disclosure
Firm disclosed “very limited and restricted information” to stock exchanges about an U.S. FDA plant audit Firm disclosed “very limited and restricted information” to stock exchanges about an U.S. FDA plant audit The Securities and Exchange Board of India (SEBI) has issued a warning letter to Aurobindo Pharma for disclosing “very limited and restricted information” […]
Continue Reading
